Indications, posology and method of administration
THERAPEUTIC INDICATIONS
In accordance with the “National Guidelines for Reproductive Health Services” issued with Decision No. 4128/QĐ-BYT dated July 29, 2016 by the Minister of Health.
POSOLOGY AND METHOD OF ADMINISTRATION
In accordance with the “National Guidelines for Reproductive Health Services” issued with Decision No. 4128/QĐ-BYT dated July 29, 2016 by the Minister of Health.
CONTRAINDICATIONS
Do not use this product if:
Absolute contraindications:
- Mitral valve stenosis, vascular occlusion, and a history of vascular occlusion.
- Adrenal gland disorders.
- Coagulation disorders, or use of anticoagulants.
- Anemia (severe and moderate).
- Allergy to mifepristone or misoprostol.
- Severe, uncontrolled asthma.
- Genetic porphyrin metabolism disorders.
Relative contraindications:
- Long-term systemic corticosteroid therapy.
- Hypertension.
- Acute genital tract infections (must be treated).
- Congenital genital abnormalities (should only be performed in central hospitals).
- History of cesarean section, with caution: reduce the misoprostol dose and increase the interval between doses (should only be performed in specialized obstetric hospitals at the provincial or central level).
For indications to terminate pregnancy up to 9 weeks and from the 10th to the 12th week, absolute contraindications include:
- Confirmed or suspected ectopic pregnancy.
- Pregnancy at the site of a previous cesarean section scar.
For indications to terminate pregnancy from the 13th to the 22nd week, absolute contraindications include:
- Previous cesarean section scar on the uterine body.
- Placenta accreta (placenta with abnormal attachment).
Refer to additional contraindications for products containing misoprostol.
Induction of labor in the case of intrauterine fetal death: If used in combination with prostaglandins, refer to the contraindications of the selected prostaglandin analogue.
© 2016 Hera Biopharm. All Rights Reserved. Designed By Herabiopharm
11.png)
.jpg)
.jpg)
.jpg)
.jpg)